• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

昂丹司琼给药与致死结局相关。

Administration of ondansetron is associated with lethal outcome.

机构信息

Clinical Genetics, Department of Pediatrics, Hospital de Cruces, Barakaldo, Spain.

出版信息

Pediatrics. 2010 Jun;125(6):e1514-7. doi: 10.1542/peds.2009-2795. Epub 2010 May 3.

DOI:10.1542/peds.2009-2795
PMID:20439600
Abstract

We report here the case of a child with a known muscular abnormality and susceptibility to malignant hyperthermia who abruptly died after receiving a therapeutic dose of ondansetron. Also, we discuss the pharmacodynamic relationship of ondansetron to malignant hyperthermia in a susceptible host.

摘要

我们在此报告一例已知肌肉异常和恶性高热易感性的儿童，在接受奥氮平治疗剂量后突然死亡。此外，我们还讨论了奥氮平在易感宿主中与恶性高热的药效学关系。

相似文献

1
Administration of ondansetron is associated with lethal outcome.昂丹司琼给药与致死结局相关。
Pediatrics. 2010 Jun;125(6):e1514-7. doi: 10.1542/peds.2009-2795. Epub 2010 May 3.
2
Identification of malignant hyperthermia-susceptible ryanodine receptor type 1 gene (RYR1) mutations in a child who died in a car after exposure to a high environmental temperature.一名儿童在暴露于高温环境后死于车内，对其进行恶性高热易感性1型兰尼碱受体基因（RYR1）突变鉴定。
Leg Med (Tokyo). 2009 May;11(3):142-3. doi: 10.1016/j.legalmed.2008.12.004. Epub 2009 Feb 14.
3
Ondansetron-induced dystonia, hypoglycemia, and seizures in a child.昂丹司琼致儿童肌张力障碍、低血糖和癫痫发作
Ann Pharmacother. 2011 Jan;45(1):e7. doi: 10.1345/aph.1P332. Epub 2010 Dec 28.
4
First choice for radiation-induced nausea and vomiting--the efficacy and safety of granisetron.放疗引起的恶心和呕吐的首选药物——格拉司琼的疗效与安全性
Acta Oncol. 2004 Sep;43 Suppl 15:19-22. doi: 10.1080/11001700410016161.
5
Core myopathies and risk of malignant hyperthermia.核心肌病与恶性高热风险
Anesth Analg. 2009 Oct;109(4):1167-73. doi: 10.1213/ANE.0b013e3181b5ae2d.
6
Statin-induced adverse effects and malignant hyperthermia susceptibility: comment on the article by Guis et al.他汀类药物引起的不良反应与恶性高热易感性：对吉斯等人文章的评论
Arthritis Rheum. 2007 Feb 15;57(1):186-7; author reply 187-8. doi: 10.1002/art.22487.
7
Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.昂丹司琼和地塞米松对接受化疗的妇科恶性肿瘤患者的止吐作用。
J Med Assoc Thai. 2006 Oct;89 Suppl 4:S29-36.
8
Identification of a novel mutation in the ryanodine receptor gene (RYR1) in a malignant hyperthermia Italian family.一个意大利恶性高热家系中兰尼碱受体基因（RYR1）新突变的鉴定。
Eur J Hum Genet. 2000 Feb;8(2):149-52. doi: 10.1038/sj.ejhg.5200428.
9
[Malignant hyperthermia--a hereditary and potentially life-threatening condition].恶性高热——一种遗传性且可能危及生命的病症
Tidsskr Nor Laegeforen. 2005 Oct 20;125(20):2792-4.
10
Prospective evaluation of ondansetron for undifferentiated nausea and vomiting in the prehospital setting.昂丹司琼用于院前未分化恶心和呕吐的前瞻性评估。
Prehosp Emerg Care. 2008 Jan-Mar;12(1):87-91. doi: 10.1080/10903120701707963.

引用本文的文献

1
Management of Suspected Malignant Hyperthermia With Dantrolene: Clinical Insights From 2 Case Reports in a Single-Center Experience.用丹曲林治疗疑似恶性高热：单中心经验中2例病例报告的临床见解
Clin Med Insights Case Rep. 2025 Jun 14;18:11795476251349345. doi: 10.1177/11795476251349345. eCollection 2025.
2
Benefit-Risk Assessment of Off-Label Drug Use in Children: The Bravo Framework.儿童超适应证用药的获益-风险评估： Bravo 框架。
Clin Pharmacol Ther. 2021 Oct;110(4):952-965. doi: 10.1002/cpt.2336. Epub 2021 Jul 29.
3
Identical de novo mutation in the type 1 ryanodine receptor gene associated with fatal, stress-induced malignant hyperthermia in two unrelated families.
两个无关联家族中，1 型兰尼碱受体基因的新发突变与致命性、应激诱导的恶性高热相关。
Anesthesiology. 2011 Nov;115(5):938-45. doi: 10.1097/ALN.0b013e3182320068.
4
Oral ondansetron administration in emergency departments to children with gastroenteritis: an economic analysis.急诊科儿童肠胃炎患者使用昂丹司琼口服制剂：一项经济学分析。
PLoS Med. 2010 Oct 12;7(10):e1000350. doi: 10.1371/journal.pmed.1000350.